Gender | Age
Item
all participants must be female and at least 21 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Oestrogen receptor positive breast cancer TNM Breast tumor staging | Breast Carcinoma Progesterone receptor positive TNM Breast tumor staging
Item
patients must have had histologically confirmed stage i-iii breast carcinoma that is positive for estrogen receptor (er) and/or progesterone receptor (pr).
boolean
C2938924 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
C0678222 (UMLS CUI [2,1])
C0279759 (UMLS CUI [2,2])
C0474926 (UMLS CUI [2,3])
Postmenopausal state
Item
post-menopausal
boolean
C0232970 (UMLS CUI [1])
Aromatase Inhibitors Adjuvant therapy Beginning
Item
beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks
boolean
C0593802 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0439659 (UMLS CUI [1,3])
Diphosphonates
Item
bisphosphonates are allowed at the treating investigator¡¦s discretion
boolean
C0012544 (UMLS CUI [1])
WHO performance status scale | ECOG performance status
Item
performance status (who/ecog scale) 0-2.
boolean
C1298650 (UMLS CUI [1])
C1520224 (UMLS CUI [2])
Kidney Calculi
Item
history of kidney stones
boolean
C0022650 (UMLS CUI [1])
Hypercalcemia
Item
hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters
boolean
C0020437 (UMLS CUI [1])
Hypercalcemia Symptomatic | Hyperparathyroidism Symptomatic
Item
history of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion
boolean
C0020437 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0020502 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Vitamin D measurement
Item
baseline vitamin d level greater than 50 ng/ml
boolean
C0919758 (UMLS CUI [1])
Protocol Compliance Unable | Protocol Compliance Unwilling
Item
inability or unwillingness to comply with, or follow study procedures.
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
Phenytoin | Phenobarbital | Cholestyramine | orlistat
Item
currently taking phenytoin or phenobarbital -7 currently taking cholestyramine or orlistat
boolean
C0031507 (UMLS CUI [1])
C0031412 (UMLS CUI [2])
C0008402 (UMLS CUI [3])
C0076275 (UMLS CUI [4])
Malabsorption Syndrome | Crohn Disease
Item
malabsorption syndrome, such as crohn's disease
boolean
C0024523 (UMLS CUI [1])
C0010346 (UMLS CUI [2])
Therapies Illicit | Calcium Additional | Vitamin D Additional | Cholestyramine | orlistat | Phenytoin | Phenobarbital
Item
prohibited therapies: patients may not take additional calcium and vitamin d aside from the study medications. patients who are on cholestyramine or orlistat will not be allowed on the trial. also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between vitamin d and anti-epileptic medications.
boolean
C0087111 (UMLS CUI [1,1])
C0332266 (UMLS CUI [1,2])
C0006675 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])
C0042866 (UMLS CUI [3,1])
C1524062 (UMLS CUI [3,2])
C0008402 (UMLS CUI [4])
C0076275 (UMLS CUI [5])
C0031507 (UMLS CUI [6])
C0031412 (UMLS CUI [7])